• Xiao-Yan Shi, Si-Min Fan, Guo-Mei Shi, Jia Yao, Yang Gao, Yu-Guo Xia, and Qiu Chen.
• Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province.
• Medicine (Baltimore). 2020 Jun 12; 99 (24): e20624.

BackgroundNon-alcoholic fatty liver disease (NAFLD), especially non-alcoholic steatohepatitis, which is considered as the hepatic manifestation of metabolic syndrome, has a great prevalence all over the world. New drugs are urgently needed for the treatment of NAFLD. This review will be to assess the efficacy and safety of omega-3 polyunsaturated fatty acids (n-3 PUFAs) on liver-related outcomes (liver histology and liver enzymes) in patients with NAFLD.MethodsWe will search 5 databases for relative studies: Medline, the Cochrane Library, EMBASE, Web of Science, and ClinicalTrials.gov and identified all reports of randomized controlled trials published prior to July 2020. Two authors will independently scan the articles searched, extract the data from articles included, and assess the risk of bias by Cochrane tool of risk of bias. Disagreements will be resolved by discussion among authors. All analysis will be performed based on the Cochrane Handbook for Systematic Reviews of Interventions. Fixed-effects model or random-effects model will be used to calculate pooled estimates of weighted mean difference with 95% confidence intervals.ResultsThis systematic review aims to examine the effect of n-3 PUFAs on liver histology and liver enzymes in patients with NAFLD.ConclusionsThese findings will provide guidance to clinicians and patients on the use of n-3 PUFAs for NAFLD.Ethics And DisseminationThis study is a protocol for a systematic review of n-3 PUFAs as a treatment of NAFLD patients. This review will be published in a journal and disseminated in print by peer-review.Systematic Review RegistrationINPLASY202050008.

29 keywords...

hide…